Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.
Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P. Gamucci T, et al. Among authors: ferrarini i. J Cancer. 2014 Mar 20;5(5):320-7. doi: 10.7150/jca.8748. eCollection 2014. J Cancer. 2014. PMID: 24723974 Free PMC article.
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Natoli C, et al. Among authors: ferrarini i. J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20. J Cancer Res Clin Oncol. 2013. PMID: 23604446 Free PMC article.
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G. Allegrini G, et al. Among authors: ferrarini i. Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140. Pharmacogenomics. 2014. PMID: 25521357 Clinical Trial.
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
Coltelli L, Fontana A, Lucchesi S, Ginocchi L, Bocci G, Filidei M, Scalese M, Arrighi G, Finale C, Marcucci L, Goletti O, Salvadori B, Ferrarini I, Bona E, Falcone A, Allegrini G. Coltelli L, et al. Among authors: ferrarini i. Breast. 2017 Feb;31:186-191. doi: 10.1016/j.breast.2016.11.006. Epub 2016 Nov 23. Breast. 2017. PMID: 27886643 Clinical Trial.
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer.
Vultaggio A, Petrella MC, Tomao F, Nencini F, Mecheri V, Marini A, Perlato M, Vivarelli E, De Angelis C, Ferrarini I, Pillozzi S, Matucci A, Antonuzzo L. Vultaggio A, et al. Among authors: ferrarini i. Gynecol Oncol Rep. 2021 Oct 12;38:100880. doi: 10.1016/j.gore.2021.100880. eCollection 2021 Nov. Gynecol Oncol Rep. 2021. PMID: 34926761 Free PMC article.
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome.
Rigo A, Vaisitti T, Laudanna C, Terrabuio E, Micillo M, Frusteri C, D'Ulivo B, Merigo F, Sbarbati A, Mellert K, Möeller P, Montresor A, Di Napoli A, Cirombella R, Butturini E, Massaia M, Constantin G, Vinante F, Deaglio S, Ferrarini I. Rigo A, et al. Among authors: ferrarini i. Cell Death Dis. 2024 May 9;15(5):323. doi: 10.1038/s41419-024-06707-5. Cell Death Dis. 2024. PMID: 38724507 Free PMC article.
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey.
Duminuco A, Romano A, Ferrarini I, Santuccio G, Chiarenza A, Figuera A, Caruso LA, Motta G, Palumbo GA, Mogno C, Moioli A, Di Raimondo F, Visco C. Duminuco A, et al. Among authors: ferrarini i. Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05752-6. Online ahead of print. Ann Hematol. 2024. PMID: 38630129
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, Giacobazzi L, Caligola S, Adamo A, Putta S, Aparo A, Ferrarini I, Ugel S, Giugno R, Donadelli M, Dando I, Krampera M, Visco C, Scupoli MT. Gambino S, et al. Among authors: ferrarini i. Sci Rep. 2024 Mar 19;14(1):6595. doi: 10.1038/s41598-024-55728-9. Sci Rep. 2024. PMID: 38503806 Free PMC article.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: ferrarini i. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
42 results